Background: The positive effects of factor treatment of hemophilia are well established, but the long-term outcomes are not well documented. This panel study evaluated changes in bleeding frequency, joint mobility, physical function, and symptoms in Danish patients with moderate to severe hemophilia A or B over 24 years. Methods: Three anonymous surveys were conducted in 1988, 2001, and 2012 targeting Danish patients with moderate to severe hemophilia, and the study participants, respectively, were 128, 156, and 164 male patients with hemophilia (PWH). The number of bleeding episodes, the use of factor concentrate, comorbidities, joint mobility, physical function, and symptoms were evaluated by means of self-reporting. Trends over time were analyzed using ordinal and multinomial logistic-regression models controlling for age group. Results: The proportion of PWH in the oldest age group (55–88 years) increased from 4% in 1988 to 18% in 2012. In 1988, a high risk of bleeding episodes was primarily found in the age group of 16–34 years. In 2012, a high risk was primarily found in the age group of 35–54 years. Joint mobility and physical function increased significantly from 1988 to 2012 but showed a noticeable decrement in the older age groups, even in 2012. Pain in the extremities, anxiety, and depression decreased significantly, but back pain increased. No significant changes were found for 7 other symptoms. Conclusions: Significant improvements in joint mobility and physical function have occurred over the last 24 years, but PWH > 35 years still experience a decline in these areas with age. This decline underscores the importance of life-long treatment and continuous rehabilitation of PWH.

1.
World Federation of Hemophilia
:
Report on the Global Survey
.
2015
; 2016.
2.
World Federation of Hemophilia
.
Guidelines for the management of hemophilia
.
Blackwell Publishing Ltd.
;
2012
.
3.
Baumgardner
J
,
Elon
L
,
Antun
A
,
Stein
S
,
Ribeiro
M
,
Slovensky
L
, et al.
Physical activity and functional abilities in adult males with haemophilia: a cross-sectional survey from a single US haemophilia treatment centre
.
Haemophilia
.
2013
Jul
;
19
(
4
):
551
7
.
[PubMed]
1351-8216
4.
Coppola
A
,
Franchini
M
,
Tagliaferri
A
.
Prophylaxis in people with haemophilia
.
Thromb Haemost
.
2009
Apr
;
101
(
4
):
674
81
.
[PubMed]
0340-6245
5.
de Kleijn
P
,
Sluiter
D
,
Vogely
HC
,
Lindeman
E
,
Fischer
K
.
Long-term outcome of multiple joint procedures in haemophilia
.
Haemophilia
.
2014
Mar
;
20
(
2
):
276
81
.
[PubMed]
1351-8216
6.
Noone
D
,
O’Mahony
B
,
van Dijk
JP
,
Prihodova
L
.
A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries
.
Haemophilia
.
2013
Jan
;
19
(
1
):
44
50
.
[PubMed]
1351-8216
7.
Ozelo
M
,
Chowdary
P
,
Regnault
A
,
Busk
AK
.
Impact of severe haemophilia A on patients’ health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) )
.
Haemophilia
.
2015
Jul
;
21
(
4
):
451
7
.
[PubMed]
1351-8216
8.
Gringeri
A
,
Lundin
B
,
von Mackensen
S
,
Mantovani
L
,
Mannucci
PM
;
ESPRIT Study Group
.
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
.
J Thromb Haemost
.
2011
Apr
;
9
(
4
):
700
10
.
[PubMed]
1538-7933
9.
Iorio
A
,
Marchesini
E
,
Marcucci
M
,
Stobart
K
,
Chan
AK
.
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
.
Cochrane Database Syst Rev
.
2011
Sep
;(
9
):
CD003429
.
[PubMed]
1469-493X
10.
Manco-Johnson
MJ
,
Abshire
TC
,
Shapiro
AD
,
Riske
B
,
Hacker
MR
,
Kilcoyne
R
, et al.
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
.
N Engl J Med
.
2007
Aug
;
357
(
6
):
535
44
.
[PubMed]
0028-4793
11.
Cavazza
M
,
Kodra
Y
,
Armeni
P
,
De Santis
M
,
López-Bastida
J
,
Linertová
R
, et al.;
BURQOL-RD Research Network
.
Social/economic costs and quality of life in patients with haemophilia in Europe
.
Eur J Health Econ
.
2016
Apr
;
17
(
S1
Suppl 1
):
53
65
.
[PubMed]
1618-7598
12.
Mondorf
W
,
Kalnins
W
,
Klamroth
R
.
Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy
.
Haemophilia
.
2013
Jul
;
19
(
4
):
558
63
.
[PubMed]
1351-8216
13.
Ingerslev
J
,
Lethagen
S
,
Hvitfeldt Poulsen
L
,
Sørensen
B
,
Lopatina
E
,
Tentsova
I
, et al.
Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients
.
Haemophilia
.
2014
Jan
;
20
(
1
):
58
64
.
[PubMed]
1351-8216
14.
Khawaji
M
,
Astermark
J
,
Berntorp
E
.
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life
.
Eur J Haematol
.
2012
Apr
;
88
(
4
):
329
35
.
[PubMed]
0902-4441
15.
Noone
D
,
O’Mahony
B
,
Prihodova
L
.
A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries
.
Haemophilia
.
2011
Sep
;
17
(
5
):
e842
3
.
[PubMed]
1351-8216
16.
Brodin
E
,
Baghaei
F
,
Sunnerhagen
KS
.
Self-reported activity and functioning in daily life; the perspective of persons with haemophilia living in Sweden
.
Eur J Haematol
.
2015
Oct
;
95
(
4
):
336
41
.
[PubMed]
0902-4441
17.
Oldenburg
J
.
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens
.
Blood
.
2015
Mar
;
125
(
13
):
2038
44
.
[PubMed]
0006-4971
18.
Fischer
K
,
Steen Carlsson
K
,
Petrini
P
,
Holmström
M
,
Ljung
R
,
van den Berg
HM
, et al.
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
.
Blood
.
2013
Aug
;
122
(
7
):
1129
36
.
[PubMed]
0006-4971
19.
Cassis
FR
,
Querol
F
,
Forsyth
A
,
Iorio
A
;
HERO International Advisory Board
.
Psychosocial aspects of haemophilia: a systematic review of methodologies and findings
.
Haemophilia
.
2012
May
;
18
(
3
):
e101
14
.
[PubMed]
1351-8216
20.
Plug
I
,
van der Bom
JG
,
Peters
M
,
Mauser-Bunschoten
EP
,
de Goede-Bolder
A
,
Heijnen
L
, et al.
Thirty years of hemophilia treatment in the Netherlands, 1972-2001
.
Blood
.
2004
Dec
;
104
(
12
):
3494
500
.
[PubMed]
0006-4971
21.
Smit
C
,
Rosendaal
FR
,
Varekamp
I
,
Bröcker-Vriends
A
,
Van Dijck
H
,
Suurmeijer
TP
, et al.
Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85
.
BMJ
.
1989
Jan
;
298
(
6668
):
235
8
.
[PubMed]
0959-8138
22.
Manco-Johnson
MJ
,
Soucie
JM
,
Gill
JC
;
Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network
.
Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project
.
Blood
.
2017
Apr
;
129
(
17
):
2368
74
.
[PubMed]
0006-4971
23.
Chang
CY
,
Li
TY
,
Cheng
SN
,
Pan
RY
,
Wang
HJ
,
Lin
SY
, et al.
Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia
.
Haemophilia
.
2017
Mar
;
23
(
2
):
284
91
.
[PubMed]
1351-8216
24.
Mannucci
PM
,
Iacobelli
M
.
Progress in the contemporary management of hemophilia: the new issue of patient aging
.
Eur J Intern Med
.
2017
Sep
;
43
:
16
21
.
[PubMed]
0953-6205
25.
Niu
X
,
Poon
JL
,
Riske
B
,
Zhou
ZY
,
Ullman
M
,
Lou
M
, et al.
Physical activity and health outcomes in persons with haemophilia B
.
Haemophilia
.
2014
Nov
;
20
(
6
):
814
21
.
[PubMed]
1351-8216
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.